Why Pertussis Is Particularly Dangerous to Newborns
Pertussis (whooping cough) is caused by *Bordetella pertussis*, a highly contagious respiratory bacterium that infects an estimated 24 million people globally each year. While most older children and adults experience pertussis as a prolonged but survivable cough illness, newborns under 2 months are uniquely vulnerable: their airways are narrow, their cough reflex is immature, and they cannot mount a robust immune response. Among US infants under 2 months who contract pertussis, approximately 50% require hospitalization, 25% develop pneumonia, 1–2% develop seizures or encephalopathy, and 1% die. Newborns cannot themselves receive their first pertussis-containing vaccine (DTaP) until 2 months of age — meaning the most dangerous window for pertussis is also a window in which the infant has no direct vaccine protection. This biologic gap is the rationale for the maternal Tdap strategy: vaccinating the pregnant person so that pertussis-specific IgG antibodies cross the placenta in the third trimester, conferring passive immunity to the newborn that lasts approximately 6–8 weeks postpartum, bridging to the first DTaP dose. CDC began universally recommending Tdap during every pregnancy in 2012 (updating earlier postpartum-only guidance) after surveillance data demonstrated that postpartum 'cocooning' was insufficient and that newborns continued to die from pertussis they acquired from undiagnosed adult contacts.
It is worth understanding that pertussis surveillance in the US has shown cyclical 3–5 year epidemic peaks, with the most recent peak in 2024–2025 producing the highest case counts since 2014. Communities with lower Tdap coverage — whether due to vaccine hesitancy, healthcare access barriers, or fragmented prenatal care — see disproportionately high infant hospitalization rates during these cycles. Maternal Tdap is the single most actionable intervention for a family during a pertussis-circulating period.
The 27–36-Week Window: Why Timing Matters
CDC and ACOG specifically recommend Tdap administration between 27 and 36 weeks of gestation, with the early end of that window preferred (27–32 weeks). The reason is antibody kinetics. After Tdap, maternal anti-pertussis IgG concentrations peak at approximately 2 weeks post-vaccination and then plateau before slowly declining. Placental antibody transfer is most efficient in the third trimester, accelerating sharply between 28 and 32 weeks. Vaccination at 27–32 weeks therefore aligns peak maternal antibody with peak transfer efficiency, delivering the highest possible newborn antibody titer at birth. Studies measuring umbilical cord antibody concentrations consistently show that Tdap at 27–32 weeks produces higher newborn antibody levels than Tdap at 33–36 weeks, which in turn is significantly better than earlier or later vaccination. A randomized trial published in *JAMA* (2014) demonstrated that infants of mothers vaccinated at 28–32 weeks had pertussis antibody concentrations 2- to 3-fold higher than infants of mothers vaccinated at 38+ weeks. Tdap is recommended in *every* pregnancy regardless of prior Tdap history — antibodies wane sufficiently that prior vaccination does not provide adequate transfer for a subsequent pregnancy. If Tdap is missed during pregnancy, postpartum vaccination is recommended (ideally before hospital discharge) to protect the newborn through cocooning, but the protection is substantially lower than antenatal vaccination.
If your prior pregnancy ended in preterm delivery before 27 weeks, Tdap can be administered as early as 20 weeks in the current pregnancy if clinically appropriate; consult your maternal-fetal medicine provider. The window is a strong recommendation, not an absolute rule — clinical judgment can shift it earlier when delivery is anticipated before the standard window.
Safety: What the Evidence Shows
Maternal Tdap has been the subject of intensive safety surveillance since 2012. The Vaccine Safety Datalink, the Vaccine Adverse Event Reporting System, and multiple cohort studies — including a 2018 study of 78,000 pregnancies — have found no association between maternal Tdap and adverse pregnancy outcomes including preterm birth, low birth weight, hypertensive disorders, chorioamnionitis, or neonatal complications. The most common side effects are identical to non-pregnant Tdap recipients: injection-site soreness (60–80%), mild fatigue, mild myalgia, and low-grade fever. Serious adverse events are exceedingly rare. ACOG, CDC's Advisory Committee on Immunization Practices (ACIP), the Society for Maternal-Fetal Medicine, and the WHO all endorse Tdap in every pregnancy. The vaccine is also safe in repeat doses if a pregnancy follows shortly after the previous one — there is no minimum interval between Tdap doses when administered for maternal antibody transfer. Tdap can be co-administered with the influenza vaccine, COVID-19 vaccine, and RSV vaccine (Abrysvo, recommended at 32–36 weeks in pertussis season-overlapping pregnancies) without reducing efficacy or increasing reactogenicity. Pregnant people with a true contraindication to Tdap — such as a documented history of anaphylaxis to a Tdap component or encephalopathy within 7 days of a prior pertussis vaccine — should consult maternal-fetal medicine for individualized counseling.
Co-administration logistics matter more than they sound. The 2023 ACIP recommendation introduced maternal RSV vaccine (Abrysvo) at 32–36 weeks for pregnancies overlapping the September–January RSV season. Tdap and Abrysvo can be given the same day in different arms, but many practices schedule them at separate visits to monitor reactogenicity — ask your provider what their protocol is and request a single-visit schedule if that better fits your calendar.
How Much Protection Does the Newborn Actually Get
Real-world effectiveness studies, conducted in multiple countries since 2012, consistently show striking newborn benefit from maternal Tdap. A landmark UK matched case-control study (Amirthalingam et al., *Lancet*, 2014) reported 91% effectiveness against pertussis in infants under 2 months whose mothers received Tdap during pregnancy. CDC's US Vaccine Effectiveness Network reported 78% effectiveness against pertussis disease and 91% effectiveness against pertussis hospitalization in infants under 2 months. Critically, infants whose mothers received Tdap during pregnancy were significantly less likely to die from pertussis than infants of unvaccinated mothers — the studies have not been powered to estimate mortality reduction precisely, but the magnitude is substantial. Maternal Tdap also slightly attenuates the *first* DTaP response in the infant (a phenomenon called blunting), but the difference is small, transient, and clinically irrelevant after the full 3-dose primary series. The trade-off — slightly lower initial DTaP response in exchange for substantially lower risk of severe disease in the most vulnerable window — strongly favors maternal vaccination. Coverage in the US, however, remains uneven: 2023 CDC data show approximately 55% of pregnant people received Tdap during pregnancy, with substantial geographic and demographic variation. Closing this gap is one of the highest-yield interventions available in newborn preventive care.
The cost barrier is essentially zero. The Affordable Care Act mandates coverage of recommended maternal vaccines with no cost-sharing, and the Vaccines for Children program covers infants of uninsured or underinsured parents. If a pharmacy or clinic attempts to charge for Tdap during pregnancy, request that the visit be coded as a preventive service and contact your insurer's prenatal care line — out-of-pocket maternal Tdap is almost always a billing error.
What to Ask Your OB or Midwife and How to Plan
If you are pregnant or planning to become pregnant, the simplest preventive action you can take for your newborn's first 8 weeks of life is to confirm a Tdap appointment between 27 and 32 weeks. Ask your obstetric provider at every prenatal visit beginning at 20 weeks: 'When are we scheduling my Tdap?' Most practices offer it at a routine third-trimester visit, but it is sometimes accidentally deferred or postponed; bringing it up proactively avoids the common late-trimester slip. If your provider does not stock Tdap, ask for a prescription or referral to a pharmacy — every major US pharmacy chain administers Tdap, and most insurance plans cover it as a preventive service with no copay. Bring up co-administration if you are also due for influenza or RSV maternal vaccine (Abrysvo); they can be given on the same day without reducing protection. After delivery, all household contacts — partners, grandparents, siblings, doulas, nannies — should be up to date on Tdap if their last booster was more than 10 years ago. The 'cocoon' is no substitute for maternal Tdap, but it adds protection during the high-risk first 2 months. If you are reading this postpartum and missed Tdap during pregnancy, request it before hospital discharge or at your first postpartum visit — the protection is reduced but not zero.
If you are postpartum and missed Tdap, the highest-yield single action is to receive it now (before hospital discharge if possible) and to ensure that every household contact — partner, grandparents, regular caregivers — is up to date. Pertussis travels efficiently in the household, and the 'cocoon' has measurable effect on infant infection rates even though it is less effective than antenatal vaccination.